Quanta Announces CEO Transition
Hooman Hakami, former Medtronic executive, named Interim CEO
BEVERLY, Massachusetts – June 30, 2022 – Quanta Dialysis Technologies Inc (“Quanta or “The Company”), a medical technology company committed to making kidney care more accessible with its SC+ hemodialysis system, announced today that CEO John E. Milad will leave the company effective July 15, 2022. The company has begun the search for a new CEO. Upon Milad’s departure and until the appointment of a new CEO, Hooman Hakami, a member of the Quanta Board of Directors, will serve as interim CEO.
“I could not be prouder of where Quanta is today, especially as the company continues to develop its transatlantic presence to scale commercially,” said John Milad, outgoing Quanta CEO. “Looking forward, Quanta will benefit from leadership that has a proven track-record in commercial expansion. I am more confident than ever of the product we have developed and the passionate and ambitious team we’ve built.”
Chairman of Quanta’s Board, Johan de Ruiter, applauded John for the leadership he has brought to the company. “On behalf of the Board, I want to thank John for his visionary leadership and unrelenting dedication to Quanta since its founding. His contributions since appointment as CEO eight years ago have positioned Quanta well for commercial success,” said de Ruiter, who added “The Board is firmly committed to the vision that has driven Quanta – the need for a better, more patient-centric kidney care option – and we are more excited than ever about the position of the Company to achieve that vision.”
Hooman is a business leader with more than 30 years of experience primarily in Healthcare and MedTech, previously serving as a member of Medtronic’s executive committee and Group President for Diabetes, a $2.5 billion division, and serving as President of Detection and Guidance Solutions at GE Healthcare, a $2.0 billion division.
“We are committed to conducting a thorough CEO search with a focus on identifying a new leader that will unlock the tremendous potential that we all believe exists in SC+ and in Quanta” said Hakami. “As we conduct the search, I will take a more engaged role to support the management team in order to ensure a seamless transition for our patients, employees, commercial partners, and shareholders,”
About Quanta and SC+
Quanta Dialysis Technologies is reinventing kidney care to be more accessible to every patient in every setting with its SC+ haemodialysis system. With performance comparable to larger, traditional machines, SC+ is a modular and powerful solution that provides the clinical versatility needed to deliver dialysis care across multiple settings. As a portable system with an intuitive simple user interface, SC+ is designed to be operated by a broad range of users to bring dialysis directly to patients.
SC+ is commercially available in the United Kingdom for home and hospital use and in the United States is FDA-cleared (K210661) for use in chronic and acute care settings.
For more information, please visit: www.quantadt.com